







CROATIA

Recent and planned changes in pharmaceutical pricing and reimbursement and overview of the medical devices system



Changes in pricing Changes in reimbursement Change of reference countries (International comparisons): There are no changes. International comparisons Old Ordinance New Ordinance Italy Italy Submit applications (company) Basic countries Slovenia Slovenia Р France Czech Republic J L Spain Spain Н CHIF (administration obligation) Reserve (backup) countries Czech Republic France Maximum prices for listed drugs determined through annual price R The Committee for Medicinal Products calculations: (13 members) up to 100% of the average price in Drugs under patent М protection basic countries A up to 100% of the average price in Drugs not under patent CHIF's Management Board protection basic countries (9 members) C Ε Maximum prices for drugs introduced to the lists for the first time: Original up to 100% of the average price in international U breakthrough drugs (ATC level 3): The criteria for inclusion: Т prescription drugs: up to 100% of the average price of -importance of the medicinal product from the similar drugs in Croatia - 90% on health insurance; 10% Me too drugs: perspective of public health hospital drugs: up to 100% of the average price of -therapeutic importance of the medicinal product C similar drugs in Croatia -relative therapeutic value of the medicinal product up to 70% of the average price in international -assessment of ethical aspects Α Generic drugs: comparisons and up to 90% of the price of the cheapest generic in Croatia up to 85% of the average price in international S Biosimilars: comparisons and up to 90% of the price of the cheapest in Croatia Internal price referencing: -clusters formed at ATC levels 3-5 -Reference price = cheapest molecule, 5% of cluster volume over a 3-month period preceding the reference pricing process Other changes related to medicines - VAT on drugs from January 2013. М Pricing and reimbursement system of medical devices • Competent authority: Competence for pricing and reimbursement lies with both Croatian Ministry of Health and Croatian Ε Health Insurance Fund; classification, clinical trials and registration (if needed) are with the Agency for Medicinal Products D and Medical Devices (HALMED) • Price regulation: Pricing of medical devices that are not reimbursed by Croatian Health Insurance Fund is statutorily not regulated and can be freely set by the manufacturers. In order to apply for the List of medical devices which are reimbursed by Croatian Health Insurance Fund, applicant needs to comply with price regulation ordinance set by Ministry D of Health. Ε • Reimbursement: Manufacturers or distributors need to make an application for the reimbursement list with Croatian Health Insurance Fund (HZZO) in order to have a medical device reimbursed. It is up to the manufacturers/distributors ٧ whether they ask for reimbursement or not. Submit application (company) – CHIF The Committee for ortnopeuto devices The Committee for general medical-technical devices - CHIF's Management Board C • Price sources/prices known: There is an overview of prices for medical devices which are reimbursed by Croatian Health Ε

Insurance Fund (i.e. List of medical devices)

S







